Finance
Banking
Advising on the laws of the BVI, the Cayman Islands, Ireland, Jersey and Luxembourg, our global Banking team of lawyers has extensive experience in advising banks and other financial institutions, private equity houses and corporates on many types of domestic and cross border banking transactions. These comprise loan and other funding arrangements, including property financing, project finance and general corporate lending. We advise both lenders and borrowers on counterparty issues as well as providing opinions covering due incorporation / establishment, capacity, authorisation, enforceability and enforcement of security interests.
Banking
We have extensive experience in advising banks and other financial institutions, private equity houses and corporates on many types of domestic and cross border banking transactions governed by British Virgin Islands, Cayman Islands, Irish, Jersey or Luxembourg law. These comprise loan and other funding arrangements, including property financing, project finance and general corporate lending.
In addition, a large component of our banking practice includes advising both lenders and borrowers on counterparty issues as well as providing opinions covering due incorporation / establishment, capacity, authorisation, enforceability and enforcement of security interests.
Related Contacts
KNOWLEDGE
- The Aviation Law Review, 10th Edition: Cayman Islands 16 August 2022
- Legal 500 - Banking and Finance Law in Ireland: the Outlook for 2022 27 July 2022
- FUNDed - June 2022 27 June 2022
- ICLG Derivatives 2022 Cayman Islands 23 June 2022
- The Regulatory 15/15: June 2022 14 June 2022
NEWS & DEALS
- Maples Group Wins Three Awards at China Business Law Awards 2022 15 June 2022
- Maples Group Wins Nine Finance Dublin Deals of the Year Awards 2022 01 June 2022
- Maples Group Welcomes 13 New Associates to its Irish Law Firm 20 May 2022
- Maples Group Announces Partner and Of Counsel Promotions in the Caribbean Region 12 May 2022
- Maples Advises on First Royalty-Backed Financing in China's Biopharmaceutical Industry 04 May 2022